01984nas a2200205   4500008004100000022001400041245013800055210006900193260000800262300001400270490000700284520122800291100002601519700001901545700002001564700002201584700001901606700002301625856013001648       2020                        eng d  a0022-152X00aSynthesis and antimycobacterial screening of new 4-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-3-yl)quinoline derivatives0 aSynthesis and antimycobacterial screening of new 441benzyl1H123t  cNOV  a3918-39290 v573 a<p>A new series of 4-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-3-yl)quinoline (6a-t) have been synthesized by a click reaction of 4-(4-ethynyl-1-phenyl-1H-pyrazol-3-yl)quinoline (4a-d) with a substituted benzyl azide (5a-e). The starting alkyne derivatives4a-dare obtained from Bestmann-Ohira reaction of 1-phenyl-3-(quinolin-4-yl)-1H-pyrazole-4-carbaldehyde and dimethyl(1-diazo-2-oxopropyl)phosphonate. The newly synthesized compounds are screened againstM. tuberculosisH37Ra dormant and active,Escherichia coli,Pseudomonas fluorescence,Staphylococcus aureusandBacillus subtilisstrains at 30 mu g/mL concentration. Most of the screened compounds showed good to moderate antibacterial activity againstS. aureus,B. subtilis, andMycobacterium tuberculosisH37Ra strains. The synthesized derivatives of quinolinyl-pyrazole-4-carbaldehyde and quinolinyl-pyrazole-4-ethyne reportd good to moderate activity against both strains ofM. tuberculosisH37Ra. Ten derivatives of quinolinyl-pyrazole presented good activity againstB. subtilis. These results suggested that further optimization and development of quinolinyl-pyrazolyl-1,2,3-triazole moeity could serve as lead compounds for antimycobacterial activity.</p>
1 aThakare, Prashant, P.1 aWalunj, Yogesh1 aChavan, Abhijit1 aBobade, Vivek, D.1 aSarkar, Dhiman1 aMhaske, Pravin, C.  uhttps://library.ncl.res.in/content/synthesis-and-antimycobacterial-screening-new-4-4-1-benzyl-1h-123-triazol-4-yl-1-phenyl-1h